Inadvertent administration of 5 times the recommended dose, infused intravenously over a 24 hour period, to an asymptomatic 16 month old patient with a blood lead content of 56 mcg/dl did not cause any ill effects. Edetate calcium disodium can aggravate the symptoms of severe lead poisoning, therefore, most toxic effects (cerebral edema, renal tubular necrosis) appear to be associated with lead poisoning. Because of cerebral edema, a therapeutic dose may be lethal to an adult or a pediatric patient with lead encephalopathy. Higher dosage of edetate calcium disodium may produce a more severe zinc deficiency.
A chelating agent (chelating agents) that sequesters a variety of polyvalent cations. It is used in pharmaceutical manufacturing and as a food additive.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Apixaban | Apixaban may increase the anticoagulant activities of Edetic acid. |
| Dabigatran etexilate | Dabigatran etexilate may increase the anticoagulant activities of Edetic acid. |
| Dasatinib | The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Edetic acid. |
| Deferasirox | The risk or severity of gastrointestinal bleeding can be increased when Edetic acid is combined with Deferasirox. |
| Ursodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Edetic acid is combined with Ursodeoxycholic acid. |
| Glycochenodeoxycholic Acid | The risk or severity of bleeding and bruising can be increased when Edetic acid is combined with Glycochenodeoxycholic Acid. |
| Cholic Acid | The risk or severity of bleeding and bruising can be increased when Edetic acid is combined with Cholic Acid. |
| Glycocholic acid | The risk or severity of bleeding and bruising can be increased when Edetic acid is combined with Glycocholic acid. |
| Deoxycholic acid | The risk or severity of bleeding and bruising can be increased when Edetic acid is combined with Deoxycholic acid. |
| Taurocholic acid | The risk or severity of bleeding and bruising can be increased when Edetic acid is combined with Taurocholic acid. |
| Obeticholic acid | The risk or severity of bleeding and bruising can be increased when Edetic acid is combined with Obeticholic acid. |
| Chenodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Edetic acid is combined with Chenodeoxycholic acid. |
| Taurochenodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Edetic acid is combined with Taurochenodeoxycholic acid. |
| Tauroursodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Edetic acid is combined with Tauroursodeoxycholic acid. |
| Bamet-UD2 | The risk or severity of bleeding and bruising can be increased when Edetic acid is combined with Bamet-UD2. |
| Dehydrocholic acid | The risk or severity of bleeding and bruising can be increased when Edetic acid is combined with Dehydrocholic acid. |
| Hyodeoxycholic Acid | The risk or severity of bleeding and bruising can be increased when Edetic acid is combined with Hyodeoxycholic Acid. |
| Edoxaban | The risk or severity of bleeding can be increased when Edoxaban is combined with Edetic acid. |
| Ibrutinib | The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Edetic acid. |
| Obinutuzumab | The risk or severity of bleeding and hemorrhage can be increased when Edetic acid is combined with Obinutuzumab. |
| Rivaroxaban | Edetic acid may increase the anticoagulant activities of Rivaroxaban. |
| Sugammadex | The risk or severity of bleeding and hemorrhage can be increased when Edetic acid is combined with Sugammadex. |
| Tibolone | Tibolone may increase the anticoagulant activities of Edetic acid. |
| Tipranavir | The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Edetic acid. |
| Urokinase | Urokinase may increase the anticoagulant activities of Edetic acid. |
| Vitamin E | Vitamin E may increase the anticoagulant activities of Edetic acid. |
| Vorapaxar | The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Edetic acid. |
| Ginkgo biloba | Ginkgo biloba may increase the anticoagulant activities of Edetic acid. |
| Ifosfamide | The risk or severity of bleeding can be increased when Ifosfamide is combined with Edetic acid. |
| Quinine | The therapeutic efficacy of Edetic acid can be increased when used in combination with Quinine. |
| Quinidine | The therapeutic efficacy of Edetic acid can be increased when used in combination with Quinidine. |
| Tamoxifen | The risk or severity of bleeding can be increased when Tamoxifen is combined with Edetic acid. |
| Toremifene | The risk or severity of bleeding can be increased when Toremifene is combined with Edetic acid. |
| Pentoxifylline | The therapeutic efficacy of Edetic acid can be increased when used in combination with Pentoxifylline. |
| Pentosan polysulfate | Pentosan polysulfate may increase the anticoagulant activities of Edetic acid. |
| Insulin human | Edetic acid may increase the hypoglycemic activities of Insulin human. |
| Insulin lispro | Edetic acid may increase the hypoglycemic activities of Insulin lispro. |
| Insulin glargine | Edetic acid may increase the hypoglycemic activities of Insulin glargine. |
| Insulin pork | Edetic acid may increase the hypoglycemic activities of Insulin pork. |
| Insulin aspart | Edetic acid may increase the hypoglycemic activities of Insulin aspart. |
| Insulin detemir | Edetic acid may increase the hypoglycemic activities of Insulin detemir. |
| Insulin glulisine | Edetic acid may increase the hypoglycemic activities of Insulin glulisine. |
| NN344 | Edetic acid may increase the hypoglycemic activities of NN344. |
| Insulin beef | Edetic acid may increase the hypoglycemic activities of Insulin beef. |
| Insulin degludec | Edetic acid may increase the hypoglycemic activities of Insulin degludec. |
| Insulin peglispro | Edetic acid may increase the hypoglycemic activities of Insulin peglispro. |
| Insulin tregopil | Edetic acid may increase the hypoglycemic activities of Insulin tregopil. |
| Insulin argine | Edetic acid may increase the hypoglycemic activities of Insulin argine. |
| Levocarnitine | The therapeutic efficacy of Edetic acid can be increased when used in combination with Levocarnitine. |
| Diethylstilbestrol | Diethylstilbestrol may decrease the anticoagulant activities of Edetic acid. |
| Chlorotrianisene | Chlorotrianisene may decrease the anticoagulant activities of Edetic acid. |
| Conjugated estrogens | Conjugated estrogens may decrease the anticoagulant activities of Edetic acid. |
| Mestranol | The risk or severity of adverse effects can be increased when Mestranol is combined with Edetic acid. |
| Estriol | Estriol may decrease the anticoagulant activities of Edetic acid. |
| Estrone sulfate | Estrone sulfate may decrease the anticoagulant activities of Edetic acid. |
| Quinestrol | Quinestrol may decrease the anticoagulant activities of Edetic acid. |
| Hexestrol | Hexestrol may decrease the anticoagulant activities of Edetic acid. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Edetic acid. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Edetic acid. |
| Polyestradiol phosphate | Polyestradiol phosphate may decrease the anticoagulant activities of Edetic acid. |
| Esterified estrogens | Esterified estrogens may decrease the anticoagulant activities of Edetic acid. |
| Zeranol | Zeranol may decrease the anticoagulant activities of Edetic acid. |
| Equol | Equol may decrease the anticoagulant activities of Edetic acid. |
| Methallenestril | Methallenestril may decrease the anticoagulant activities of Edetic acid. |
| Epimestrol | Epimestrol may decrease the anticoagulant activities of Edetic acid. |
| Moxestrol | Moxestrol may decrease the anticoagulant activities of Edetic acid. |
| Estradiol acetate | Estradiol acetate may decrease the anticoagulant activities of Edetic acid. |
| Estradiol benzoate | Estradiol benzoate may decrease the anticoagulant activities of Edetic acid. |
| Estradiol cypionate | Estradiol cypionate may decrease the anticoagulant activities of Edetic acid. |
| Estradiol valerate | Estradiol valerate may decrease the anticoagulant activities of Edetic acid. |
| Biochanin A | Biochanin A may decrease the anticoagulant activities of Edetic acid. |
| Formononetin | Formononetin may decrease the anticoagulant activities of Edetic acid. |
| Limaprost | The risk or severity of adverse effects can be increased when Limaprost is combined with Edetic acid. |
| Icosapent | The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Edetic acid. |
| Mesalazine | The risk or severity of bleeding can be increased when Mesalazine is combined with Edetic acid. |
| Indomethacin | The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Edetic acid. |
| Nabumetone | The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Edetic acid. |
| Ketorolac | The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Edetic acid. |
| Tenoxicam | The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Edetic acid. |
| Celecoxib | The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Edetic acid. |
| Tolmetin | The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Edetic acid. |
| Rofecoxib | The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Edetic acid. |
| Piroxicam | The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Edetic acid. |
| Fenoprofen | The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Edetic acid. |
| Valdecoxib | The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Edetic acid. |
| Diclofenac | The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Edetic acid. |
| Sulindac | The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Edetic acid. |
| Flurbiprofen | The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Edetic acid. |
| Etodolac | The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Edetic acid. |
| Mefenamic acid | The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Edetic acid. |
| Naproxen | The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Edetic acid. |
| Sulfasalazine | The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Edetic acid. |
| Phenylbutazone | The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Edetic acid. |
| Meloxicam | The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Edetic acid. |
| Carprofen | The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Edetic acid. |
| Diflunisal | The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Edetic acid. |
| Salicylic acid | The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Edetic acid. |
| Meclofenamic acid | The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Edetic acid. |
| Oxaprozin | The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Edetic acid. |
| Ketoprofen | The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Edetic acid. |